Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Onbrez

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Dry powder inhalers (DPIs) are breath actuated devices relying on the inhalation effort generated by the patients during the… Expand
  • figure 2.1
  • figure 2.2
  • table 2-1
  • figure 2.3
  • figure 2.4
Is this relevant?
2017
2017
Onbrez Breezhaler® is a low-resistance capsule-based device that was developed to deliver indacaterol maleate. The study was… Expand
  • table I
  • table II
  • table III
  • figure 1
  • table IV
Is this relevant?
2017
2017
Indacaterol, as well glycopyronium has been reimbursed lately in Poland, so patients have a greater access to this treatment in… Expand
Is this relevant?
2017
2017
Background Inhaled indacaterol (Onbrez Breezhaler), a long-acting β2-agonist, is approved in over 100 countries, including South… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2015
2015
서론: 만성기도질환에 대한 체계적인 환자 교육은 환자의 증상 및 삶의 질을 개선시킬 것으로 기대되나, 처방된 흡입기의 종류 및 중증도에 따라 교육 효과에 차이가 있을 수 있다. 방법: 1차 의원을 방문한 천식 및 COPD… Expand
Is this relevant?
Review
2011
Review
2011
Indacaterol is a novel ultra long-acting beta 2-agonist (ultra-LABA), given once-daily, developed for the treatment of Chronic… Expand
Is this relevant?
Review
2010
Review
2010
Indacaterol (Onbrez), previously known as QAB-149-AFA, is a novel ultra-long-acting beta2-adrenoceptor agonist that was recently… Expand
Is this relevant?
Review
2010
Review
2010
Indacaterol (Onbrez) is a new long-acting beta2-agonist taken once daily for the treatment of COPD. In our New products review… Expand
Is this relevant?
2009
2009
  • 2009
  • Corpus ID: 37363059
 
Is this relevant?